Soricimed Biopharma adds deep public markets experience to team with appointment of healthcare veteran Frank Michalargias as CFO

Frank Michalargias

Closely-held Soricimed Biopharma, an oncology drug developer, appointed healthcare industry veteran Frank Michalargias as CFO. 

In a finance and operations leadership career spanning more than 25 years, Mr. Michalargias has held senior roles at both private and publicly traded companies across various industries. 

He most recently served as CFO at Helix Biopharma, where he was responsible for external and internal financial reporting; risk management; corporate governance; forecasting; treasury and capital market initiatives. He also served as CFO of AP Plasman, Trailmobile and Multy Industries, as well as the senior finance director at CFM.

In a statement, Robert Bruce, CEO of Soricimed, said Mr. Michalargian’s “extensive and demonstratable record of accomplishment in helping companies navigate change and growth, more than half of which was built within the pharmaceutical and biotechnology industry, will be a tremendous asset to Soricimed as we continue to advance our key clinical programs.”

Mr. Michalargian said it’s an exciting time to be joining Soricimed and he looks forwards to “helping the company execute its strategic plan and deliver value for its shareholders.”